TransMedics Group, Inc. (TMDX) Q3 2026 earnings results
TransMedics Group, Inc. (TMDX) reported Q3 2026 results on Nov 5, 2026, 4:02:14 PM ET: adjusted EPS $0.51 vs. $0.29 expected (beat by 73.8%); revenue $203.00M vs. $177.11M expected (beat by 14.6%). Outlook: Full-year 2026 revenue guidance raised to $764-$774 million, including PAD Aviation.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $0.51 | $0.29 | Beat by 73.8% |
| Revenue | $203.00M | $177.11M | Beat by 14.6% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:02:14 PM ET. Nexqual published them 38 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 41.1% from $143.82M.
Stock reaction
The results came out after the market closed. TMDX closed at $88.24 on November 6, 2026, up 27.9% from its $68.98 close on November 5, 2026 before the results. Latest: $90.81 as of 11:40 AM ET, +31.6% since the pre-release close.
Questions and answers
Did TransMedics Group, Inc. beat earnings expectations?
Yes. TransMedics Group, Inc. reported adjusted EPS of $0.51 against an average analyst estimate of $0.29 (beat by 73.8%), and revenue of $203.00M against $177.11M expected (beat by 14.6%).
What were TransMedics Group, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of $0.51 and revenue of $203.00M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 41.1% from $143.82M.
When did TransMedics Group, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:02:14 PM ET, in an SEC 8-K filing (Item 2.02).
How did TMDX stock react to the earnings?
The results came out after the market closed. TMDX closed at $88.24 on November 6, 2026, up 27.9% from its $68.98 close on November 5, 2026 before the results. Latest: $90.81 as of 11:40 AM ET, +31.6% since the pre-release close.
What did TransMedics Group, Inc. say about its outlook?
Full-year 2026 revenue guidance raised to $764-$774 million, including PAD Aviation.
More on TMDX
TMDX stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt